<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Remdesivir, a nucleotide analog GS-5734 that produced by biotechnology company Gilead, has a certain anti-coronal virus effect in animal experiments [
 <xref ref-type="bibr" rid="CR54">54</xref>]. In addition, Remdesivir can improve lung function, reduce lung viral load and severe lung pathology in mice [
 <xref ref-type="bibr" rid="CR51">51</xref>]. A study reported that an American patient with COVID-19 survived by treated with Remdesivir [
 <xref ref-type="bibr" rid="CR55">55</xref>]. At the same time, a study showed that 68% of the 53 patients with severe and critical new coronavirus have relieved symptoms and the mortality rate is 13% after the use of Remdesivir [
 <xref ref-type="bibr" rid="CR56">56</xref>]. However, the study was conducted under sympathetic medication, and there was no control group, so it was not possible to evaluate the direct relationship between Remdesivir and patientsâ€™ symptom improvement. Although the test results released a certain positive signal, the test has limitations and still needs follow-up discussion.
</p>
